Structures by: Norberg B.
Total: 115
Beta-cyclodextrin Aegelinol clathrate hydrate
C42H70O35,C14H14O4,0.25(O2),9.25(H2O),2(O)
Crystals (2012) 2, 4 1441-1454
a=15.4039(12)Å b=15.2813(12)Å c=17.8904(14)Å
α=99.6620(10)° β=113.4230(10)° γ=102.4810(10)°
Aegelinol
C14H14O4
Crystals (2012) 2, 4 1441-1454
a=6.8921(3)Å b=11.4302(9)Å c=44.964(3)Å
α=90.00° β=90.00° γ=90.00°
C22H23NO3
C22H23NO3
Organic & biomolecular chemistry (2006) 4, 21 3898-3900
a=11.945(1)Å b=11.653(2)Å c=16.339(2)Å
α=90.00° β=127.717(7)° γ=90.00°
C24H24N2O4
C24H24N2O4
Organic & biomolecular chemistry (2006) 4, 21 3898-3900
a=17.576(3)Å b=15.667(2)Å c=7.4650(10)Å
α=90.00° β=90.461(11)° γ=90.00°
Tetrakis(N-methylimidazole)copper(II) bistriflimide
C22H32CuF6N9O4S2,C2F6NO4S2
CrystEngComm (2012) 14, 15 4902
a=8.991(2)Å b=9.438(3)Å c=14.654(3)Å
α=89.594(15)° β=72.209(13)° γ=62.905(13)°
Tetrakis(N-methylimidazole)copper(II) bistriflimide
C32H48CuF12N10O8S4
CrystEngComm (2012) 14, 15 4902
a=16.0369(6)Å b=24.0453(9)Å c=25.0434(9)Å
α=90.00° β=90.651(2)° γ=90.00°
Hexakis(N-methylimidazole)cobalt(II) bistriflimide
C24H36CoN12,2(C2F6NO4S2)
CrystEngComm (2012) 14, 15 4902
a=8.2207(2)Å b=20.3211(4)Å c=27.0612(5)Å
α=90.00° β=92.363(2)° γ=90.00°
Hexakis(N-methylimidazole)nickel(II) bistriflimide
C24H36N12Ni,2(C2F6NO4S2)
CrystEngComm (2012) 14, 15 4902
a=8.2018(2)Å b=20.3183(5)Å c=26.9380(8)Å
α=90.00° β=92.341(3)° γ=90.00°
Hexakis(N-methylimidazole)copper(II) bistriflimide
C24H36CuN12,2(C2F6NO4S2)
CrystEngComm (2012) 14, 15 4902
a=8.2933(3)Å b=11.1971(3)Å c=24.1682(7)Å
α=91.145(1)° β=93.419(1)° γ=92.945(2)°
L-Prolinium cocrystal of S-Naproxen
C14H14O3,C5H9NO2
CrystEngComm (2013) 15, 17 3341
a=5.6999(2)Å b=6.5428(3)Å c=23.1874(10)Å
α=90.00° β=94.835(4)° γ=90.00°
D-Prolinium cocrystal of S-Naproxen
C14H14O3,C5H9NO2
CrystEngComm (2013) 15, 17 3341
a=5.7713(2)Å b=6.2520(3)Å c=23.8346(11)Å
α=90.00° β=92.047(4)° γ=90.00°
DL-Prolinium cocrystal of RS-Naproxen
C14H14O3,C5H9NO2,H2O
CrystEngComm (2013) 15, 17 3341
a=6.1054(2)Å b=12.4750(5)Å c=49.1664(13)Å
α=90.00° β=90.00° γ=90.00°
L-Prolinium cocrystal of RS-Naproxen
C14H14O3,C5H9NO2,H2O
CrystEngComm (2013) 15, 17 3341
a=13.122(2)Å b=5.8980(10)Å c=24.075(3)Å
α=90.00° β=95.560(5)° γ=90.00°
Tetrakis(N-methylimidazole)copper(II) bistriflimide
C20H24CuF12N10O8S4
CrystEngComm (2012) 14, 15 4902
a=9.1104(5)Å b=9.6323(5)Å c=10.6590(7)Å
α=68.139(4)° β=85.255(5)° γ=87.828(4)°
4-(2-Methoxyphenyl)-4-thiazoline-2-thione
C10H9NOS2
Acta Crystallographica Section C (2016) 72, 5 421-425
a=8.42280(10)Å b=7.90820(10)Å c=16.2102(3)Å
α=90° β=97.152(2)° γ=90°
4-(4-Methoxyphenyl)-4-thiazoline-2-thione
C10H9NOS2
Acta Crystallographica Section C (2016) 72, 5 421-425
a=4.7187(3)Å b=12.0438(7)Å c=17.8972(11)Å
α=90° β=93.752(6)° γ=90°
C57H104O6
C57H104O6
Acta Crystallographica Section B (2000) 56, 2 317-321
a=11.6650(12)Å b=44.933(5)Å c=5.432(6)Å
α=87.034(10)° β=100.17(9)° γ=89.09(9)°
C8H14N2O2
C8H14N2O2
Acta Crystallographica Section B (2013) 69, 4 371-378
a=9.5932(3)Å b=7.8325(3)Å c=11.9547(4)Å
α=90.00° β=103.830(3)° γ=90.00°
C8H14N2O2
C8H14N2O2
Acta Crystallographica Section B (2013) 69, 4 371-378
a=9.3020(8)Å b=11.5223(7)Å c=8.4172(5)Å
α=90.00° β=95.966(7)° γ=90.00°
C8H14N2O2,H2O
C8H14N2O2,H2O
Acta Crystallographica Section B (2013) 69, 4 371-378
a=7.2006(5)Å b=7.9639(5)Å c=9.5468(6)Å
α=85.293(5)° β=76.031(6)° γ=70.023(6)°
C6H10N2O2
C6H10N2O2
Acta Crystallographica Section B (2011) 67, 6 499-507
a=6.5030(10)Å b=6.4180(10)Å c=16.416(3)Å
α=90.00° β=92.087(4)° γ=90.00°
11<i>S</i>,13<i>R</i>,16<i>R</i>,18<i>S</i>,22<i>S</i>-1-Azonia-9-ethyl-3- hydroxy-5-(6-methoxy-quinolin-4-yl)-3-methyl- 4-oxatricyclo[6.2.2.0]dodecane trifluoromethanesulfonate
C23H31N2O3,CF3SO3
Acta Crystallographica Section E (2006) 62, 7 o2864-o2865
a=11.3120(10)Å b=8.0590(10)Å c=14.0740(10)Å
α=90.00° β=101.490(10)° γ=90.00°
8,8'-dichloro-1,1',5,5'-tetrahydro-10,10'-bipyrrolo[1,2-b] isoquinolin-3,3'(2H,2'H)-dione
C24H18Cl2N2O2
Acta Crystallographica Section E (2003) 59, 7 o1002-o1003
a=8.1130(10)Å b=12.0890(10)Å c=20.181(2)Å
α=90.00° β=92.79(3)° γ=90.00°
Ethyl 2-cyclopentoxy-4-hydroxy-5-ethyl-6-methylnicotinate
C16H23NO4
Acta Crystallographica Section E (2002) 58, 8 o964-o965
a=6.3120(10)Å b=10.5710(10)Å c=12.396(2)Å
α=84.205(7)° β=77.098(8)° γ=88.827(5)°
N-methyl-N-(4-nitro-2-phenoxyphenyl)methanesulfonamide
C14H14N2O5S
Acta Crystallographica Section E (2001) 57, 11 o1012-o1013
a=14.5220(10)Å b=10.4390(10)Å c=10.5230(10)Å
α=90.00° β=109.460(4)° γ=90.00°
N-{[2-carboxy-5-oxopyrrolidin-1-yl](p-tolyl)methyl}pyroglutamic acid
C18H20N2O6
Acta Crystallographica Section E (2001) 57, 5 o439-o440
a=9.0770(10)Å b=11.0650(10)Å c=17.1060(10)Å
α=90.00° β=90.00° γ=90.00°
Dimethyl 2-((1S)-1-((4S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-methyl-2- nitropropyl) malonate
C14H23NO8
Acta Crystallographica Section C (1998) 54, 6 834-837
a=8.003(5)Å b=11.253(5)Å c=18.461(5)Å
α=90.000(5)° β=90.000(5)° γ=90.000(5)°
Dimethyl (3S)-3-((4S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2,2- dimethylcyclopropane-1,1-dicarboxylate
C14H22O6
Acta Crystallographica Section C (1998) 54, 6 834-837
a=7.32010(10)Å b=10.7190(10)Å c=19.3900(10)Å
α=90.000(6)° β=90.000(4)° γ=90.000(5)°
Methyl (3S)-2-acetyl-3-((4S)-2,2-dimethyl-1,3-dioxolan-4-yl)-4-methyl- (phenylsulfonyl) pentanoate
C20H28O8S
Acta Crystallographica Section C (1998) 54, 6 834-837
a=10.6930(10)Å b=8.4460(10)Å c=11.9920(10)Å
α=90.00° β=101.268(5)° γ=90.00°
(1S)-phenyl-1-[(2S)-(3,5-dinitrobenzoyloxy)-propyl]-(2R)-methyl cyclopentane
C22H24N2O6
Acta Crystallographica Section C (1998) 54, 9 1353-1355
a=6.1890(10)Å b=10.6140(10)Å c=16.1600(10)Å
α=90.00° β=100.993(4)° γ=90.00°
C11H13NO4
C11H13NO4
Acta Crystallographica Section C (1994) 50, 1 97-100
a=11.546(6)Å b=9.360(2)Å c=4.922(3)Å
α=90.0° β=101.5(2)° γ=90.0°
C12H15NO4
C12H15NO4
Acta Crystallographica Section C (1994) 50, 1 97-100
a=7.295(3)Å b=25.653(5)Å c=6.321(2)Å
α=90.° β=90.° γ=90.°
(5,2'-dithien-2-yl)-2'-deoxyuridine
C17H16N2O5S2
Acta Crystallographica Section C (1997) 53, 7 892-895
a=14.580(2)Å b=18.5345(10)Å c=6.44770(10)Å
α=90.00° β=90.00° γ=90.00°
PGlu-Pro-NH~2~
C10H17N3O4
Acta Crystallographica Section C (1997) 53, 4 477-480
a=10.154(2)Å b=8.968(2)Å c=6.749(2)Å
α=90.00° β=104.00(20)° γ=90.00°
((1R,2S,4R,5S,6S)-exo-2-acetoxy-3,3,endo-6-trimethylbicyclo[3.1.0] hexan-exo-4-yl) camphanoate
C21H30O6
Acta Crystallographica Section C (1998) 54, 3 392-398
a=9.5450(10)Å b=32.428(5)Å c=6.8100(10)Å
α=90.00° β=90.00° γ=90.00°
C21H30O6
C21H30O6
Acta Crystallographica Section C (1998) 54, 3 392-398
a=14.7140(10)Å b=11.0010(10)Å c=14.736(2)Å
α=90.00° β=118.527(8)° γ=90.00°
((1R,2S,4R,5S)-exo-2-acetoxy-3,3-dimethylbicyclo[3.1.0]hexan-exo-4-yl) camphanoate
C20H28O6
Acta Crystallographica Section C (1998) 54, 3 392-398
a=11.5461(11)Å b=12.2484(7)Å c=7.169(5)Å
α=90.00° β=102.487(4)° γ=90.00°
((1S,2S,4R,5R,6S)-exo-2-acetoxy-endo-6-(3-butenyl)-3,3,exo-6- trimethylbicyclo[3.1.0]hexan-exo-4-yl) camphanoate
C25H36O6
Acta Crystallographica Section C (1998) 54, 3 392-398
a=15.5800(10)Å b=12.8890(10)Å c=6.23600(10)Å
α=90.00° β=99.051(4)° γ=90.00°
2-phenyl-cis-4,6-dimethyl-1,3-diselenane
C12H16Se2
Acta Crystallographica Section C (1998) 54, 10 1505-1507
a=8.582(5)Å b=9.609(5)Å c=31.213(5)Å
α=90.000(5)° β=90.000(5)° γ=90.000(5)°
(1S^*^,3S^*^)-3-methoxy-1-methyl-3-phenyl-3-(1,1,1-trimethylsilyl)-propyl 3,5-dinitrobenzoate.
C21H26N2O7Si
Acta Crystallographica Section C (1998) 54, 12 1944-1945
a=32.421(3)Å b=6.2350(10)Å c=22.6460(10)Å
α=90.00° β=91.333(7)° γ=90.00°
(+-)-2-Benzoyl-8-ethyl-1,2-dihydroisoquinoline-1-carbonitrile
C19H16N2O
Acta Crystallographica Section E (2007) 63, 7 o3161-o3161
a=7.9960(10)Å b=8.9480(10)Å c=11.297(2)Å
α=108.51(2)° β=94.860(10)° γ=93.040(10)°
3-methyl-1-[4-(methylsulfonyl)phenyl]-5-phenyl-1H-pyrazole
C17H16N2O2S
Acta Crystallographica Section C (2004) 60, 9 o648-o652
a=11.0070(10)Å b=13.0610(10)Å c=24.2980(10)Å
α=90.00° β=112.652(5)° γ=90.00°
Ethyl 1-[4-(methylsulfonyl)phenyl]-5-phenyl-1H-pyrazole-3-carboxylate
C19H18N2O4S
Acta Crystallographica Section C (2004) 60, 9 o648-o652
a=19.4790(10)Å b=5.6100(10)Å c=33.586(3)Å
α=90.00° β=90.00° γ=90.00°
2-methyl-6-(4,4,4-trifluorobutoxy)-9H-indeno[1,2-c]pyridazin-9-one
C16H13F3N2O2
Acta Crystallographica Section C (2004) 60, 9 o623-o626
a=4.918(2)Å b=11.978(6)Å c=24.659(5)Å
α=90.00° β=96.65(2)° γ=90.00°
6-methoxy-2-[3-(trifluoromethyl)phenyl]-9H-indeno[1,2-c]pyridazin-9-one
C19H11F3N2O2
Acta Crystallographica Section C (2004) 60, 9 o623-o626
a=10.3060(10)Å b=10.7980(10)Å c=14.9860(10)Å
α=73.453(6)° β=79.592(7)° γ=89.422(7)°
1-[4-(methylsulfonyl)phenyl]-3-[3-(morpholino)phenoxymethyl]-5-phenyl-1H- pyrazole
C27H27N3O4S
Acta Crystallographica Section C (2004) 60, 9 o648-o652
a=10.325(2)Å b=13.874(2)Å c=18.094(2)Å
α=100.823(9)° β=104.704(8)° γ=91.888(11)°
7-methoxy-2-[3-(trifluoromethyl)phenyl]-9H-indeno[1,2-c]pyridazin-9-one
C19H11F3N2O2
Acta Crystallographica Section C (2004) 60, 9 o623-o626
a=7.768(2)Å b=8.750(2)Å c=12.703(2)Å
α=89.010(10)° β=81.59(2)° γ=68.050(10)°
{4(S)-(Piperidin-1-ylcarbonyl)-4-[3- (trifluoromethyl)benzenesulfonamido]butyl}guanidinium chloride
C18H27F3N5O3S,Cl
Acta Crystallographica Section C (2006) 62, 12 o691-o693
a=8.3710(10)Å b=9.3510(10)Å c=29.554(3)Å
α=90.00° β=90.00° γ=90.00°
C12H11N3O2S
C12H11N3O2S
Acta Crystallographica Section C (2002) 58, 2 o69-o71
a=6.2190(10)Å b=12.163(2)Å c=15.8550(10)Å
α=90° β=91.130(10)° γ=90°
N-(3-phenoxy-4-pyridyl)methanesulfonamide
C12H12N2O3S
Acta Crystallographica Section C (2002) 58, 2 o88-o89
a=8.0590(10)Å b=12.1160(10)Å c=24.744(2)Å
α=90° β=90° γ=90°
C12H13N3O2S
C12H13N3O2S
Acta Crystallographica Section C (2002) 58, 2 o69-o71
a=14.7380(10)Å b=5.7500(10)Å c=15.8980(10)Å
α=90° β=105.020(10)° γ=90°
N-tert-Butyl-N'-[(2-cyclohexylamino-5-nitrobenzene)sulfonyl]urea
C17H26N4O5S
Acta Crystallographica Section C (2002) 58, 10 o621-o623
a=14.447(5)Å b=11.579(5)Å c=24.981(5)Å
α=90° β=95.195(5)° γ=90°
2-{4-[(3-butyl-1,4-dioxo-2,3-diazaspiro[4.4]non-2-yl)methyl]benzamido}benzoic acid
C26H29N3O5
Acta Crystallographica Section C (2001) 57, 11 1330-1332
a=16.1220(10)Å b=12.6820(10)Å c=11.9200(10)Å
α=90° β=97.139(7)° γ=90°
2-{4-[(3-butyl-1,4-dioxo-2,3-diazaspiro[4.4]non-2-yl)methyl]benzoyl}benzoic acid
C26H28N2O5
Acta Crystallographica Section C (2001) 57, 11 1330-1332
a=10.5300(10)Å b=11.4690(10)Å c=11.4910(10)Å
α=109.589(8)° β=112.690(8)° γ=97.640(9)°
2-{4-[(3-butyl-1,4-dioxo-2,3-diazaspiro[4.4]non-2-yl)methyl]amilinocarbonyl} benzoic acid monohydrate
C26H29N3O5,H2O
Acta Crystallographica Section C (2001) 57, 11 1330-1332
a=18.6810(10)Å b=9.5650(10)Å c=14.8370(10)Å
α=90° β=111.904(7)° γ=90°
Terbogrel
C23H27N5O2
Acta Crystallographica Section C (2000) 56, 10 1265-1266
a=14.9340(10)Å b=10.1150(10)Å c=15.7400(10)Å
α=90.00° β=113.049(5)° γ=90.00°
7-nitroindazole
C7H5N3O2
Acta Crystallographica Section C (2000) 56, 10 e474-e475
a=5.0200(10)Å b=9.6360(10)Å c=14.5060(10)Å
α=90.00° β=98.232(4)° γ=90.00°
5-(3,4,5-trimethoxyphenyl)-1,2,3,5,12,12a-hexahydronaphto[1,2-f] indolizine-3,12-dione
C25H23NO5
Acta Crystallographica Section C (2000) 56, 2 193-196
a=10.8680(10)Å b=12.9370(10)Å c=15.0490(10)Å
α=90.00° β=96.009(4)° γ=90.00°
Methyl N-[4-methoxyphenyl-(3,4,5-trimethoxyphenyl)-methyl]pyroglutamate
C23H27NO7
Acta Crystallographica Section C (2000) 56, 2 193-196
a=8.4810(10)Å b=14.2060(10)Å c=18.2730(10)Å
α=90.00° β=90.538(4)° γ=90.00°
5-(3,4,5-trimethoxyphenyl)-1,2,3,5-tetrahydro-11a-naphto[1,8-f,g] indolizine-3-one
C24H23NO4
Acta Crystallographica Section C (2000) 56, 2 193-196
a=9.9090(10)Å b=8.5190(10)Å c=23.7930(10)Å
α=90.00° β=98.104(4)° γ=90.00°
Methyl N-[naphtyl-(3,4,5-trimethoxyphenyl)-methyl]pyroglutamate
C28H30NO8
Acta Crystallographica Section C (2000) 56, 2 193-196
a=9.1900(10)Å b=11.3330(10)Å c=14.7560(10)Å
α=89.292(7)° β=73.923(5)° γ=66.722(7)°
Methyl 4-{cis-2-[3-fluoro-5-(4-methoxy-3,4,5,6-tetrahydro-2H-pyran- 4-yl)phenoxymethyl]-6-hydroxy-3-phenylmorpholino}benzenesulfinate
C30H34FNO7S
Acta Crystallographica Section C (2006) 62, 2 o92-o94
a=7.151(3)Å b=21.430(4)Å c=18.274(3)Å
α=90.00° β=95.479(10)° γ=90.00°
Phenyl 2,3,4-tri-<i>O</i>-benzyl-1-thio-α-D-mannopyranoside monohydrate
C33H34O5S,H2O
Acta Crystallographica Section E (2010) 66, 7 o1525
a=12.6280(10)Å b=8.0840(10)Å c=14.832(2)Å
α=90.00° β=101.380(5)° γ=90.00°
<i>endo</i>-3,3-Dimethyl-4-oxobicyclo[3.1.0]hexan-2-yl methanesulfonate
C9H14O4S
Acta Crystallographica Section E (2010) 66, 4 o948
a=5.8558(3)Å b=7.7497(4)Å c=12.2527(6)Å
α=84.290(4)° β=79.531(4)° γ=72.070(5)°
IB07
C19H13N3O6
Acta Crystallographica Section E (2011) 67, 8 o2116
a=7.0569(3)Å b=15.5302(8)Å c=7.6947(4)Å
α=90.00° β=95.415(4)° γ=90.00°
C8H14N2O2,C6H10O4
C8H14N2O2,C6H10O4
Crystal Growth & Design (2014) 14, 6 2880
a=12.9082(9)Å b=11.5417(8)Å c=12.5179(9)Å
α=90.00° β=116.342(9)° γ=90.00°
Levetiracetam 2,2-dimethylsuccinic acid cocrystal
C8H14N2O2,C6H10O4
Crystal Growth & Design (2014) 14, 6 2880
a=6.23877(7)Å b=11.55362(12)Å c=11.34360(12)Å
α=90.00000° β=90.9259(9)° γ=90.00000°
C8H14N2O2,C7H6O4
C8H14N2O2,C7H6O4
Crystal Growth & Design (2014) 14, 6 2880
a=6.2828(3)Å b=13.3843(6)Å c=18.7984(8)Å
α=90.00° β=96.638(4)° γ=90.00°
Etiracetam 2,4-dihydroxybenzoic acid cocrystal
C8H14N2O2,C7H6O4
Crystal Growth & Design (2014) 14, 6 2880
a=6.60584(3)Å b=13.11919(7)Å c=18.80723(8)Å
α=90.00000° β=90.00000° γ=90.00000°
C8H14N2O2,C7H5NO4
C8H14N2O2,C7H5NO4
Crystal Growth & Design (2014) 14, 6 2880
a=5.8455(2)Å b=11.6845(12)Å c=12.5762(10)Å
α=78.856(8)° β=82.443(6)° γ=84.035(7)°
C8H14N2O2,2(C7H5NO4)
C8H14N2O2,2(C7H5NO4)
Crystal Growth & Design (2014) 14, 6 2880
a=8.0511(4)Å b=13.0536(6)Å c=23.0243(9)Å
α=90.00° β=90.00° γ=90.00°
C8H14N2O2,2(C7H5NO4)
C8H14N2O2,2(C7H5NO4)
Crystal Growth & Design (2014) 14, 6 2880
a=24.2697(8)Å b=7.4683(2)Å c=13.3230(5)Å
α=90.00° β=104.663(4)° γ=90.00°
2(C7H5NO4),C8H14N2O2
2(C7H5NO4),C8H14N2O2
Crystal Growth & Design (2014) 14, 6 2880
a=7.0988(9)Å b=7.3613(10)Å c=12.1428(13)Å
α=77.496(10)° β=88.250(10)° γ=74.232(12)°
C8H14N2O2,C2H2O4
C8H14N2O2,C2H2O4
Crystal Growth & Design (2014) 14, 6 2880
a=5.7253(2)Å b=20.2528(7)Å c=10.9457(5)Å
α=90.00° β=100.085(4)° γ=90.00°
C8H14N2O2,C2H2O4
C8H14N2O2,C2H2O4
Crystal Growth & Design (2014) 14, 6 2880
a=5.7646(4)Å b=19.8963(14)Å c=11.0690(8)Å
α=90.00° β=99.331(6)° γ=90.00°
Stanozolol / malonic acid cocrystal
C21H32N2O,C3H4O4
Crystal Growth & Design (2014) 14, 7 3408
a=10.6644(7)Å b=7.2335(5)Å c=15.0947(10)Å
α=90.00° β=106.016(7)° γ=90.00°
Stanozolol / D-phenyllactic acid cocrystal
2(C21H32N2O),C9H10O3,C2H3N
Crystal Growth & Design (2014) 14, 7 3408
a=58.6098(12)Å b=7.5624(2)Å c=10.7139(4)Å
α=90.00° β=97.989(2)° γ=90.00°
Stanozolol / 6-hydroxy-2-naphthoic acid
C21H32N2O,C11H8O3
Crystal Growth & Design (2014) 14, 7 3408
a=7.9530(6)Å b=8.6403(7)Å c=10.4582(7)Å
α=83.337(6)° β=86.973(6)° γ=75.431(7)°
2(C10H16N2O2),C4H6O6
2(C10H16N2O2),C4H6O6
Crystal Growth & Design (2014) 14, 8 3996
a=10.7203(7)Å b=9.3534(4)Å c=14.3581(11)Å
α=90.00° β=110.236(8)° γ=90.00°
C8H14N2O2,C5H8O4
C8H14N2O2,C5H8O4
Crystal Growth & Design (2014) 14, 8 3996
a=12.0408(8)Å b=5.9067(3)Å c=12.1169(8)Å
α=90.00° β=113.961(8)° γ=90.00°
C8H14N2O2,C5H8O4
C8H14N2O2,C5H8O4
Crystal Growth & Design (2014) 14, 8 3996
a=5.9628(4)Å b=11.5797(8)Å c=22.5983(18)Å
α=90° β=95.615(8)° γ=90°
C13H18O2,C8H14N2O2
C13H18O2,C8H14N2O2
Crystal Growth & Design (2014) 14, 8 3996
a=7.351(2)Å b=9.780(3)Å c=29.993(5)Å
α=90.00° β=90.00° γ=90.00°
C15H13FN2O
C15H13FN2O
Crystal Growth & Design (2015) 15, 8 4005
a=20.3160(18)Å b=5.2050(3)Å c=13.5364(14)Å
α=90.00° β=114.387(12)° γ=90.00°
C15H13ClN2O
C15H13ClN2O
Crystal Growth & Design (2015) 15, 8 4005
a=18.549(3)Å b=13.827(2)Å c=5.3162(7)Å
α=90.00° β=90.00° γ=90.00°
C15H13BrN2O
C15H13BrN2O
Crystal Growth & Design (2015) 15, 8 4005
a=7.0276(4)Å b=7.7445(5)Å c=25.6078(13)Å
α=90.00° β=90.00° γ=90.00°
C16H16N2O
C16H16N2O
Crystal Growth & Design (2015) 15, 8 4005
a=8.2225(4)Å b=5.7932(3)Å c=14.5687(6)Å
α=90.00° β=90.377(4)° γ=90.00°
C16H16N2O2
C16H16N2O2
Crystal Growth & Design (2015) 15, 8 4005
a=8.6581(7)Å b=5.1375(3)Å c=15.7993(10)Å
α=90.00° β=100.982(7)° γ=90.00°
C21H18N2O
C21H18N2O
Crystal Growth & Design (2015) 15, 8 4005
a=8.3299(3)Å b=5.7214(2)Å c=17.5391(5)Å
α=90.00° β=91.143(3)° γ=90.00°
C16H16N2O2
C16H16N2O2
Crystal Growth & Design (2015) 15, 8 4005
a=25.096(2)Å b=5.6957(4)Å c=20.3318(15)Å
α=90.00° β=107.199(6)° γ=90.00°
C15H13N3O3
C15H13N3O3
Crystal Growth & Design (2015) 15, 8 4005
a=7.1806(6)Å b=7.7128(7)Å c=25.267(2)Å
α=90.00° β=90.00° γ=90.00°
C16H16N2O
C16H16N2O
Crystal Growth & Design (2015) 15, 8 4005
a=5.1707(5)Å b=13.2714(12)Å c=20.434(2)Å
α=90.00° β=90.00° γ=90.00°
C16H16N2O
C16H16N2O
Crystal Growth & Design (2015) 15, 8 4005
a=5.2563(5)Å b=9.7698(12)Å c=26.617(3)Å
α=90.00° β=90.00° γ=90.00°
C16H16N2O2
C16H16N2O2
Crystal Growth & Design (2015) 15, 8 4005
a=5.1883(6)Å b=9.8853(10)Å c=27.403(3)Å
α=90.00° β=90.00° γ=90.00°
C15H13ClN2O
C15H13ClN2O
Crystal Growth & Design (2015) 15, 8 4005
a=5.4131(2)Å b=13.2515(6)Å c=18.5144(9)Å
α=90.00° β=90.00° γ=90.00°
C15H13ClN2O
C15H13ClN2O
Crystal Growth & Design (2015) 15, 8 4005
a=5.20340(10)Å b=9.7982(2)Å c=26.4764(5)Å
α=90.00° β=90.00° γ=90.00°
C15H13N3O3
C15H13N3O3
Crystal Growth & Design (2015) 15, 8 4005
a=5.2320(4)Å b=13.7900(13)Å c=18.6379(17)Å
α=90.00° β=90.00° γ=90.00°
C21H32N2O,C5H8O4
C21H32N2O,C5H8O4
Crystal Growth & Design (2014) 14, 8 3996
a=6.88070(10)Å b=11.0656(2)Å c=16.4085(3)Å
α=90.00° β=96.713(2)° γ=90.00°
C15H13FN2O
C15H13FN2O
Crystal Growth & Design (2015) 15, 8 4005
a=6.8172(8)Å b=7.9216(9)Å c=12.594(2)Å
α=90.00° β=103.040(16)° γ=90.00°
C15H13ClN2O
C15H13ClN2O
Crystal Growth & Design (2015) 15, 8 4005
a=6.7343(4)Å b=8.0362(4)Å c=12.9186(7)Å
α=90.00° β=100.314(6)° γ=90.00°
C15H13BrN2O
C15H13BrN2O
Crystal Growth & Design (2015) 15, 8 4005
a=6.7098(4)Å b=8.0495(4)Å c=13.1003(8)Å
α=90.00° β=98.867(6)° γ=90.00°